Litcius/Paper detail

Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021

Kathleen Dooling, Julia W. Gargano, Danielle Moulia, Megan Wallace, Hannah G. Rosenblum, Amy Blain, Stephen C. Hadler, Ian D. Plumb, Heidi L. Moline, Jack Gerstein, Jennifer P. Collins, Monica Godfrey, Doug Campos‐Outcalt, Rebecca L. Morgan, Oliver Brooks, H. Keipp Talbot, Grace M. Lee, Matthew F. Daley, Sara E. Oliver

2021MMWR Morbidity and Mortality Weekly Report41 citationsDOIOpen Access PDF

Abstract

for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years for the prevention of COVID-19.

Topics & Concepts

MedicineInterimAdvisory committeePediatricsFamily medicineLawPublic administrationPolitical scienceSARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyViral gastroenteritis research and epidemiology
Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021 | Litcius